Listing 13.23
Cancers of the female genital tract — carcinoma or sarcoma (including primary peritoneal carcinoma)
This listing covers cancers of the female reproductive organs — the uterus, cervix, vulva, vagina, fallopian tubes, and ovaries — plus primary peritoneal carcinoma in women (evaluated under path E because it behaves like ovarian cancer).
Read the full plain-language explanation
Each organ has its own path describing spread, invasion of other organs, or disease that persists or returns after treatment. Small cell carcinoma anywhere in the tract also qualifies. Only one path (A–F) is needed. Carcinoma-in-situ (preinvasive cancer) does not count.
Upload your medical records
PDFs or photos (JPG, PNG) — up to 15 files, 20 MB each.
What Listing 13.23 asks for
What SSA looks for — see the 6 items
We will check your records against each of these. Every item comes straight from SSA's own listing.
- Cancer of the body of the uterus qualifies if it has grown into neighboring organs, spread to or past nearby lymph nodes, or is still present or came back after the first course of treatment.
- Any one of the three is enough.
Read the original wording
Cancer of the body of the uterus qualifies if it has grown into neighboring organs, spread to or past nearby lymph nodes, or is still present or came back after the first course of treatment. Any one of the three is enough.
(Listing 13.23, criterion A)
- Cervical cancer qualifies if it has extended to the pelvic wall, the lower vagina, or other organs
- If it persists or came back after the first treatment
- If it spread to distant lymph nodes such as the para-aortic or supraclavicular nodes. Any one of the three is enough.
Read the original wording
Cervical cancer qualifies if it has extended to the pelvic wall, the lower vagina, or other organs; if it persists or came back after the first treatment; or if it spread to distant lymph nodes such as the para-aortic or supraclavicular nodes. Any one of the three is enough.
(Listing 13.23, criterion B)
- Cancer of the vulva or vagina qualifies if it has grown into neighboring organs, spread to or past nearby lymph nodes, or persists or came back after the first treatment.
- Any one of the three is enough.
Read the original wording
Cancer of the vulva or vagina qualifies if it has grown into neighboring organs, spread to or past nearby lymph nodes, or persists or came back after the first treatment. Any one of the three is enough.
(Listing 13.23, criterion C)
- Fallopian tube cancer qualifies if it has grown to the outer surface (serosa) of the tube or beyond, or if it persists or came back after the first treatment.
- Either one is enough.
Read the original wording
Fallopian tube cancer qualifies if it has grown to the outer surface (serosa) of the tube or beyond, or if it persists or came back after the first treatment. Either one is enough.
(Listing 13.23, criterion D)
- Ovarian cancer (other than germ-cell type) qualifies if it has spread beyond the pelvis (for example, deposits on the peritoneum, omentum, or bowel), spread to or past nearby lymph nodes, or came back after the first treatment.
- Germ-cell ovarian cancer qualifies only if it is growing or came back after the first treatment.
- Primary peritoneal carcinoma in women is also evaluated here.
- One qualifying finding is enough.
Read the original wording
Ovarian cancer (other than germ-cell type) qualifies if it has spread beyond the pelvis (for example, deposits on the peritoneum, omentum, or bowel), spread to or past nearby lymph nodes, or came back after the first treatment. Germ-cell ovarian cancer qualifies only if it is growing or came back after the first treatment. Primary peritoneal carcinoma in women is also evaluated here. One qualifying finding is enough.
(Listing 13.23, criterion E)
The cancer is the small cell (oat cell) type. The pathology diagnosis alone is enough.
(Listing 13.23, criterion F)
How long it must last:
No listing-specific duration stated. Under 13.00H2, an impairment meeting this listing is considered disabling until at least 3 years after onset of complete remission.